Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | PPM1D | O15297 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867606 | 0.74 | PPM1D (0.43) | L3MBTL1NPC1PPM1DALDH1A1SMN1; SMN2 | |
| SCHEMBL9392326 | 0.72 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1 | |
| SCHEMBL9392284 | 0.71 | GRIN1 (0.40) | ALDH1A1 | |
| SCHEMBL11180540 | 0.71 | KMT2A (0.52) | NPC1RAB9ACHEK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25909564 | 0.71 | KMT2A (0.52) | NPC1RAB9ACHEK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31276700 | 0.71 | KMT2A (0.52) | NPC1RAB9ACHEK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24834978 | 0.70 | KMT2A (0.44) | L3MBTL1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL11228193 | 0.69 | KMT2A (0.58) | CHEK2PPM1DALDH1A1MEN1KMT2A | |
| SCHEMBL11184150 | 0.69 | KMT2A (0.53) | NPC1RAB9ACHEK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6963348 | 0.68 | LOXL2 (0.54) | NPC1PPM1DALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, FCGR1A | L3MBTL1 959/4885NPC1 4263/4885RAB9A 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.